A global scientific strategy to cure hepatitis B

Peter Revill(The Royal Melbourne Hospital), Francis V. Chisari(Scripps Research Institute), Joan M. Block(Hepatitis B Foundation), Maura Dandri(Universität Hamburg), Adam J. Gehring(University of Toronto), Haitao Guo(Indiana University School of Medicine), Jianming Hu(Pennsylvania State University), Anna Kramvis(University of the Witwatersrand), Pietro Lampertico(University of Milan), Harry L.A. Janssen(University of Toronto), Massimo Levrero(Inserm), Wenhui Li(National Institute of Biological Sciences, Beijing), T. Jake Liang(National Institutes of Health), Seng Gee Lim(National University of Singapore), Fengmin Lu(Peking University), Capucine Pénicaud(Peter Doherty Institute), John E. Tavis(Saint Louis University), Robert Thimme(University of Freiburg), Patrick Arbuthnot(Inserm), André Boonstra, Kyong‐Mi Chang, Per-Jei Chen, Dieter Glebe, Luca G. Guidotti, Jacques Fellay, Carlo Ferrari, Louis Jansen, Daryl Lau, Anna S. Lok, Mala K. Maini, William Mason, Gail Matthews, Dimitrios Paraskevis, Jörg Petersen, Barbara Rehermann, Eui‐Cheol Shin, Alexander Thompson, Florian van Bömmel, Fusheng Wang, Koichi Watashi, Hung‐Chih Yang, Zhenghong Yuan, Man‐Fung Yuen, Timothy M. Block, Veronica Miller(Hepatitis B Foundation), Ulrike Protzer, Christian Bréchot, Stephen Locarnini, Marion G. Peters, Raymond F. Schinazi, Fabien Zoulim(Inserm)
˜The œLancet. Gastroenterology & hepatology
April 10, 2019
Cited by 494Open Access
Full Text

Abstract

Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure. We believe that research must focus on the discovery of interventional strategies that will permanently reduce the number of productively infected cells or permanently silence the covalently closed circular DNA in those cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous resolution of HBV infection. There is also a pressing need for the establishment of repositories of standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout the world. The HBV cure research agenda outlined in this position paper will contribute markedly to the goal of eliminating HBV infection worldwide.


Related Papers

No related papers found

Powered by citation graph analysis